Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

8.940 +0.310 (+3.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 508,819
Open 8.580
Bid (Size) 8.880 (3)
Ask (Size) 9.550 (1)
Prev. Close 8.630
Today's Range 8.510 - 9.100
52wk Range 6.575 - 22.93
Shares Outstanding 75,480,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire

Performance

YTD
-20.81%
-20.81%
1 Month
-1.54%
-1.54%
3 Month
-9.61%
-9.61%
6 Month
+15.50%
+15.50%
1 Year
-48.38%
-48.38%

More News

Read More
ETNB Stock Earnings: 89bio Misses EPS for Q1 2024
Via InvestorPlace
89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the BofA Securities 2024 Health Care Conference
From 89bio, Inc.
Via GlobeNewswire
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH
From 89bio, Inc.
Via GlobeNewswire
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
From 89bio, Inc.
Via GlobeNewswire
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
Via The Motley Fool
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
89bio to Participate in the Leerink Partners Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
Via Investor's Business Daily
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
From 89bio, Inc.
Via GlobeNewswire
Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
Via Investor's Business Daily
89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
Via Benzinga
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From 89bio, Inc.
Via GlobeNewswire
89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From 89bio, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.